Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Overview of attention for article published in Health and Quality of Life Outcomes, June 2017

Altmetric Badge

Mentioned by

twitter: 1 tweeter
facebook: 1 Facebook page

reddit: 1 Redditor

Citations

dimensions_citation: 24 Dimensions

Readers on

mendeley: 117 Mendeley

Summary Twitter Facebook Reddit Dimensions citations

So far, Dimensions has found 24 publications that cite this research output.

24

The most recent citing publications are shown below. View all 24 publications that cite this research output on Dimensions.

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

Article in The Lancet Oncology (June 2023)

Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

Article in Global & Regional Health Technology Assessment (April 2023)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)

Article in Cancers (March 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.